<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114566</url>
  </required_header>
  <id_info>
    <org_study_id>17-211</org_study_id>
    <nct_id>NCT03114566</nct_id>
  </id_info>
  <brief_title>Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors</brief_title>
  <official_title>Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain lymphocyte collections from normal healthy volunteer
      donors in order to create Good Manufacturing Practice grade banks of virus-specific and
      tumor-reactive T-cells of defined HLA type and restricting HLA allele readily available for
      therapeutic use.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Generation of T-cells</measure>
    <time_frame>1 year</time_frame>
    <description>Blood and/or white cell donations will be used for the generation of the T-cells to be used for adoptive immunotherapy.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Consenting healthy donor</arm_group_label>
    <description>Transplant and healthy HLA typed donors</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.</description>
    <arm_group_label>Consenting healthy donor</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Transplant donors and healthy HLA typed volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Donors must satisfy standards including those set forth by FACT (Foundation for the
             Accreditation of Cellular Therapy) and the criteria specified in FDA 21 Code of
             Federal Regulations (CFR) 1271. Specifically, screening for risk factors for
             communicable disease as well as infectious disease screening by serologic and PCR
             testing as outlined below. Including testing for IV, Hepatitis B, Hepatitis C, HTLV I
             and II, CMV, EBV, and toxoplasmosis, westnile virus, syphilis, varicella zoster, and
             Chagas disease.

          -  Donors must be typed for HLA-A, B, C, DR and DQ at high resolution.

          -  Donors accrued at MSKCC must have a hemoglobin value &gt; 10g/dl

          -  Donors must be capable of undergoing, at least, a single standard 2 blood volume
             leukapheresis or a donation of one unit of whole blood

          -  Donors must weight &gt;/= 25 kg

        Exclusion Criteria:

          -  HTLV/HIV (+) or Hepatitis B or C positive donors

          -  Donors who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Prockop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Prockop, MD</last_name>
    <phone>212-639-6715</phone>
    <email>prockops@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel-Angel Perales, MD</last_name>
    <phone>212-639-8682</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Prockop, MD</last_name>
      <phone>212-639-6715</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transplant donor</keyword>
  <keyword>HLA typed</keyword>
  <keyword>17-211</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

